Parkinson’s driven by inflammation, genetics and the environment

Parkinson’s driven by inflammation, genetics and the environment

Publication date: Feb 12, 2020

Standaert directs the Morris K. Udall Center of Excellence in Parkinson’s Disease Research, one of eight such centers funded by the National Institute of Neurological Disorders and Stroke Written by Jesse Saffron, Ph. D., National Institute of Environmental Health Sciences. Used by permission -The reality is that today, we still don’t have a treatment that slows or alters the progression of Parkinson’s disease,” said David Standaert, M. D., Ph. D. -The reality is that today, we still don’t have a treatment that slows or alters the progression of Parkinson’s disease,” said David Standaert, M. D., Ph. D., during a Jan. 8 talk at the National Institute of Environmental Health Sciences. At UAB, Standaert directs the Morris K. Udall Center of Excellence in Parkinson’s Disease Research, one of eight such centers funded by the National Institute of Neurological Disorders and Stroke. One of his research questions is whether immune system responses to a protein called alpha-synuclein trigger is a cornerstone of research in Parkinson’s disease,” Standaert told the audience. -To study the mechanisms responsible for Parkinson’s disease, there is a need for model systems that replicate the effects of environmental toxins,” Standaert said.

Concepts Keywords
Alabama Disease systems
Bear Progression ofParkinsons disease
Birmingham Palsy
Bloodletting Disorder
Brain Bowel disease psoriasis
Dopamine Responsible Parkinsons disease
Genetic Stroke
Immune System Anti inflammatory drugs
Immunity Branches of biology
Inflammation Medical specialties
Inflammatory Bowel Disease Proteins
Interact Peripheral membrane proteins
James Parkinson Geriatrics
Magnitude Parkinson’s disease
Morris Udall Psychiatric diagnosis
Multiple Sclerosis RTT
Mutation Alpha-synuclein
Neurology Anti-inflammatory
Neurons Alpha
NIEHS
Parkinson
Pesticides
Pittsburgh
Psoriasis
UAB

Semantics

Type Source Name
disease MESH inflammation
disease MESH Neurological Disorders
disease MESH Stroke
drug DRUGBANK Nonoxynol-9
disease MESH Palsy
drug DRUGBANK Tropicamide
drug DRUGBANK Dopamine
disease MESH inflammatory bowel disease
disease MESH psoriasis
disease MESH multiple sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *